



## **IntegraGen Partners with Twist Bioscience and Selects Improved Next-Generation Sequencing Exome Enrichment Solution for its Clinical Research Products**

**– First Company in France to Augment Product Line with Twist Bioscience Core Exome Kit –**

**ÉVRY, FRANCE** – January 24, 2018 – IntegraGen (FR0010908723: ALINT - PEA-SME Eligible), a company specializing in the decoding of the human genome with a focus on producing interpretable genomic analyses for academic and private laboratories in addition to developing diagnostic tools in oncology, today announced the addition of Twist Bioscience Corporation's Human Core Exome Complete Kit, a streamlined library prep and exome enrichment solution, to its next-generation targeted sequencing product offerings.

"IntegraGen is once again demonstrating its leadership position by becoming the first company in France to offer our differentiated, customizable enrichment solution as a critical component of its clinical research service offering," said Emily M. Leproust, Ph.D., CEO of Twist Bioscience. "We look forward to partnering with IntegraGen to assist them with the optimization of their robust solutions for clinical and genomics researchers worldwide."

Under the terms of the agreement Twist Bioscience will provide IntegraGen its Human Core Exome Complete Kit for all target sequencing workflow including exome sequencing for clinical research.

"After an extensive evaluation of several different providers including the possibility of moving to a whole genome sequencing approach, we selected the Twist Bioscience platform based on its improved performance and versatility for customization," said Bernard Courtieu, IntegraGen's Chief Executive Officer. "We look forward to integrating the Twist Bioscience products into our next-generation sequencing (NGS) services to offer market leading uniform sequence coverage while maintaining specificity to reduce the overall cost of sequencing for a wide range of clinical and genomics research applications."

### **About Twist Bioscience Corporation**

At Twist Bioscience Corporation, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and data storage, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. For more information about our products and services, please visit [www.twistbioscience.com](http://www.twistbioscience.com). Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at <https://twitter.com/TwistBioscience>.

## **About IntegraGen**

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2016, IntegraGen had 38 employees and had generated revenue of €6.2 million in 2017. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Euronext Growth (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information, visit [www.integragen.com](http://www.integragen.com)

### **INTEGRAGEN CONTACTS**

#### **IntegraGen**

Bernard COURTIEU  
President and CEO

Laurence RIOT LAMOTTE  
Chief Financial Officer  
[contact@integragen.com](mailto:contact@integragen.com)  
Tel.: +33 (0)1 60 91 09 00

#### **NewCap**

Investor and Media Relations  
Louis-Victor DELOUVRIER  
[integragen@newcap.eu](mailto:integragen@newcap.eu)  
Tel.: +33 (0)1 44 71 98 53

### **TWIST BIOSCIENCE CONTACTS**

#### **Investor Contact:**

Argot Partners  
Maeve Conneighton  
212-600-1902  
[maeve@argotpartners.com](mailto:maeve@argotpartners.com)

#### **Media Contact:**

Angela Bitting  
925-202-6211  
[media@twistbioscience.com](mailto:media@twistbioscience.com)